ArticleCancer research communications2021

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.

Yang Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.